...Martin Nicklasson On behalf of the Board of Directors and Executive Board, I am pleased to welcome you to the Annual General Meeting 2023 of Zealand Pharma A/S. Today, the Board of Directors is represented by myself as Chairman and the Executive Board is represented by CEO, Adam Steensberg; and CFO, Henriette Wennicke. I would like to thank our shareholders for your attendance and continued support of the company. A year ago, we announced a change in strategy. We choose to prioritize investments in research and development. Zealand's core strength, as many of you already know, is the design and development of therapeutic peptides, and this has led to a rich pipeline of promising candidates targeting rare diseases, obesity and inflammation. The company has demonstrated its ability to independently bring a product from discovery to market through the launch of Zegalogue in the U.S. However, Zealand also knows that to reach more patients in more regions around the world, the company should...
